Radioiodine therapy in patients with Graves′ disease and the effects of prior carbimazole therapy
The use of radioiodine as the first line of treatment in Graves′ disease is restricted in India because of its limited availability and an unrealistic risk perception associated with it. Additionally, the effectiveness of radioiodine ablation in Graves′ disease is influenced by many factors. Prior m...
Main Authors: | Arun Karyampudi, Abdoul Hamide, Dhanapathi Halanaik, Jaya Prakash Sahoo, Sadishkumar Kamalanathan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2014;volume=18;issue=5;spage=688;epage=693;aulast=Karyampudi |
Similar Items
-
Concomitant lithium increases radioiodine uptake and absorbed doses per administered activity in graves’ disease: comparison of conventional versus lithium-augmented radioiodine therapy
by: Fadi Khreish, et al.
Published: (2024-04-01) -
Low iodine diet does not improve the efficacy of radioiodine for the treatment of Graves’ disease
by: Vanessa A. Santarosa, et al.
Published: (2015-09-01) -
Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
by: Aleksandra Kukulska, et al.
Published: (2020-08-01) -
2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
by: Furio Pacini, et al.
Published: (2023-01-01) -
Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis
by: Michael Oeverhaus, et al.
Published: (2023-04-01)